Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma

References

• Swerdlow SH, Campo E, Harris NL, et al. Who classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer (IARC); 2017.
   Google Scholar
• Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–2418.
   PubMed Web of Science ®Google Scholar
• Pentsova E, Deangelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol. 2014;117(1):161–165.
   PubMed Web of Science ®Google Scholar
• Fox CP, Phillips EH, Smith J, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell ly mphoma. Br J Haematol. 2019;184(3):348–363.
   PubMed Web of Science ®Google Scholar
• Wen T, Wang J, Shi Y, et al. Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35(2):312–332. e-pub ahead of print 2020/10/31; doi:10.1038/s41375-020-01072-6.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016;42(3):279–290. e-pub ahead of print 2015/06/27; doi:10.1111/nan.12259.
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–843. e835. e-pub ahead of print 2017/05/30; doi:10.1016/j.ccell.2017.04.012.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blo J Am Soc Hemat. 2016;127(7):869–881.
   Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926. e-pub ahead of print 2015/07/21; doi:10.1038/nm.3884.
   PubMed Web of Science ®Google Scholar
• Goldwirt L, Beccaria K, Ple A, et al. Ibrutinib brain distribution: a preclinical study. Cancer Chemoth Pharm. 2018;81(4):783–789. e-pub ahead of print 2018/02/25; doi:10.1007/s00280-018-3546-3.
   PubMed Web of Science ®Google Scholar
• Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121–130. e-pub ahead of print 2019/07/07; doi:10.1016/j.ejca.2019.05.024.
   PubMed Web of Science ®Google Scholar
• Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–1029. e-pub ahead of print 2017/06/18; doi:10.1158/2159-8290.CD-17-0613.
   PubMed Web of Science ®Google Scholar
• Wu C, de Miranda NF, Chen L, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutat ions. Oncotarget. 2016;7(25):38180–38190.
   PubMedGoogle Scholar
• Chamoun K, Choquet S, Boyle E, et al. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: a retrospective case series. Neurology. 2017;88(1):101–102.
   PubMed Web of Science ®Google Scholar
• Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019;133(5):436–445.
   PubMed Web of Science ®Google Scholar
• Houillier C, Chabrot CM, Moles-Moreau MP, et al. Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Ser ies of the LOC Network. Neurology. 2021;97(13):628–631.
   PubMed Web of Science ®Google Scholar
• Narita Y, Nagane M, Mishima K, et al. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23(1):122–133. e-pub ahead of print 2020/06/26; doi:10.1093/neuonc/noaa145.
   PubMed Web of Science ®Google Scholar
• Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23(18):3151–3171. e-pub ahead of print 2004/04/20; doi:10.1038/sj.onc.1207542.
   PubMed Web of Science ®Google Scholar
• Au KM, Wang AZ, Park SI. Pretargeted delivery of PI3 K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non- Hodgkin's lymphoma. Sci Adv. 2020;6(14):eaaz9798.
   PubMed Web of Science ®Google Scholar
• Dreyling MH, Hess G, Woike M, et al. Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or re fractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. Ann Oncol. 2018;29(Suppl 8):viii362.
   Google Scholar
• Tessoulin B, Bouabdallah K, Burroni B, et al. Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T(3) phase IB trial of the LYSA. Ann Hematol. 2020;99(8):1771–1778. e-pub ahead of print 2020/07/01; doi:10.1007/s00277-020-04159-3.
   PubMed Web of Science ®Google Scholar
• Kuhn JG, Chang SM, Wen PY, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent mal ignant glioma. Clin Cancer Res. 2007;13(24):7401–7406.
   PubMed Web of Science ®Google Scholar
• Korfel A, Schlegel U, Herrlinger U, et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol. 2016;34(15):1757–1763. e-pub ahead of print 2016/03/16; doi:10.1200/JCO.2015.64.9897.
   PubMedGoogle Scholar
• Grommes C, Pentsova E, Nolan C, et al. Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Ann Oncol. 2016;27(suppl_6): vi3–vi3.
   Google Scholar
• Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell Non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803–2811. e-pub ahead of print 2015/07/22; doi:10.1200/JCO.2014.59.5363.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622–1627. e-pub ahead of print 2011/01/14; doi:10.1093/annonc/mdq626.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(30):4952–4957. e-pub ahead of print 2008/07/09; doi:10.1200/JCO.2007.15.3429.
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol. 2019;30(4):621–628.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595–1607. e-pub ahead of print 2018/07/11; doi:10.1182/bloodadvances.2017014845.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a Randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol. 2021;39(12):1329–1338. doi:10.1200/jco.20.01375.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Chiappella A, Gascoyne RD, et al. Robust: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untrea ted Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2021;39(12):1317–1328.
   PubMed Web of Science ®Google Scholar
• Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. Br J Haematol. 2020;189(1):84–96.
   PubMed Web of Science ®Google Scholar
• Houillier C, Choquet S, Touitou V, et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology. 2015;84(3):325–326.
   PubMed Web of Science ®Google Scholar
• Li Z, Qiu Y, Personett D, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013;8(8):e71754. e-pub ahead of print 2013/08/14; doi:10.1371/journal.pone.0071754.
   PubMed Web of Science ®Google Scholar
• Tun HW, Johnston PB, DeAngelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018;132(21):2240–2248.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3073.
   PubMed Web of Science ®Google Scholar
• Chan TSY, Khong PL, Au-Yeung R, et al. Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma. Ann Hematol. 2019;98(9):2227–2230. e-pub ahead of print 2019/07/28; doi:10.1007/s00277-019-03758-z.
   PubMed Web of Science ®Google Scholar
• Furuse M, Nonoguchi N, Omura N, et al. Immunotherapy of nivolumab with dendritic cell vaccination Is effective against intractable recurrent primary central nervous system lymphoma: A case report. Neurol Med Chir (Tokyo). 2017;57(4):191–197. e-pub ahead of print 2017/03/24; doi:10.2176/nmc.cr.2016-0330.
   PubMed Web of Science ®Google Scholar
• Ambady P, Szidonya L, Firkins J, et al. Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. Leuk Lymphoma. 2019;60(2):515–518.
   PubMed Web of Science ®Google Scholar
• Roemer MG, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018;36(10):942.
   PubMed Web of Science ®Google Scholar